Clinical Trial Update: Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a Natriuretic Peptide Receptor 1 (NPR1) antagonist in adults with Postural Orthostatic Tachycardia Syndrome (POTS) is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postural Orthostatic Tachycardia Syndrome

Drugs mentioned

• Natriuretic Peptide Receptor 1 antagonist (NPR1 antagonist)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Postural Orthostatic Tachycardia Syndrome (POTS) | Phase 2 | Status: RECRUITING